INDV — Indivior
Median target
$49
calls from the last 12 months
Implied return
+37.3%
median target vs. price
Coverage
6 analysts · 7 calls
updated in the last 12 months
Consensus
6/0/0+6 net
Buy / Hold / Sell
Which analysts are behind INDV's consensus?
See every current rating, price target and the analysts' track records for Indivior — plus the full analyst rankings, firm analytics and screener.
The consensus above reflects 6 analysts with calls on INDV updated in the last 12 months. Implied return is the move implied if the consensus target were hit. These are forward-looking predictions, not realized returns. Per-analyst ratings and track records are a Premium feature.
INDV elsewhere on AnalystEdge
The most recent congressional, executive-branch and insider filings matched to this ticker. Matched by ticker symbol — occasional mismatches are possible. Not investment advice.
Trending today: not in any of today's trending tables (Gaining attention, Losing attention, Most followed)
| Date | Source | Who | Action | Detail | Amount |
|---|---|---|---|---|---|
| 2026-08-27 | Insiders | Anderson Woodrow DChief Accounting Officer | Insider purchase | 1.5K sh @ $35.69 | $54K |
| 2026-08-05 | Insiders | Anderson Woodrow DChief Accounting Officer | Insider purchase | 1.5K sh @ $36.28 | $54K |
| 2026-01-30 | Executive | Trump, Donald JPresident | Transaction | Indivior Pharmaceuticals, Inc. | $15,001 - $50,000 |
More: insider activity · executive branch · trending